BIMERVAX®, emulsion for injection

The information contained on this global HIPRA website is not intended for audiences in all countries.

General, scientific or technical information about HIPRA products or services is not intended for commercial promotion.

For specific information on the products or services available in your country, please filter by the corresponding country.

Select your country

Vaccines

BIMERVAX®, emulsion for injection

BIMERVAX®, COVID-19 adjuvanted recombinant protein vaccine.

Summary of product characteristics

Package Leaflet

^{Marketing authorization in the}^{European Union}^{since 30 March 2023 and in the}^{United Kingdom}^{since 31 July 2023.}

Update date: 16/10/23

^{This medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are invited to report suspected adverse reactions.}